'We're All on the Same Team'. Perspectives on the Future of Artificial Pancreas Systems by Adults in Australia with Type 1 Diabetes Using Open-source Technologies: A Qualitative Study
Overview
Authors
Affiliations
Aims: An emerging group of people with type 1 diabetes are not waiting for commercial solutions, choosing to manage their condition with open-source artificial pancreas systems (APS). Our aim was to explore their perspectives on the future of APS.
Methods: Semi-structured telephone interviews were conducted (in Australia, October 2018 to January 2019) with 23 adults with type 1 diabetes currently using open-source APS. Interviews were recorded, transcribed and analysed thematically.
Results: Participants described five key features of open-source APS they value: compatibility, user-led design, customisability, ability to evolve faster and community-driven. They attributed the success of the open-source APS movement to benefits they derive from these features: choice, solutions that meet their needs, ownership, staying one step ahead and real-time support. They expressed hope that future commercial products and healthcare would benefit from their learnings and from collaboration with the open-source APS community.
Conclusions: Participants believed that there will always be a place for the open-source community. It will continue to build on and advance commercial products, respond to user needs, offering a higher degree of control and customisation than afforded by commercial products and generating optimism for the future. Participants desired that future commercial diabetes technologies would be inspired by the open-source community and developed collaboratively with people with diabetes.
Huang Q, Ni Y, Lei M, Ling P, Yan J, Guo X BMJ Open. 2025; 15(1):e094333.
PMID: 39819904 PMC: 11751815. DOI: 10.1136/bmjopen-2024-094333.
Morrison A, Chong K, Lai V, Farnsworth K, Senior P, Lam A JMIR Diabetes. 2022; 7(4):e40326.
PMID: 36279156 PMC: 9641512. DOI: 10.2196/40326.
Morrison A, Chong K, Senior P, Lam A PLoS One. 2022; 17(8):e0271096.
PMID: 35951597 PMC: 9371307. DOI: 10.1371/journal.pone.0271096.